Harvard Bioscience Inc (HBIO) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.044x

Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has a cash flow conversion efficiency ratio of 0.044x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($325.00K) by net assets ($7.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Harvard Bioscience Inc market capitalisation for the company's overall valuation and market capitalisation.

Harvard Bioscience Inc - Cash Flow Conversion Efficiency Trend (1999–2025)

This chart illustrates how Harvard Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Harvard Bioscience Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Harvard Bioscience Inc ranked by their cash flow conversion efficiency. Explore Harvard Bioscience Inc (HBIO) cash flow quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Sangshin Electronics Co. Ltd
KQ:263810
-0.063x
Aligos Therapeutics Inc
NASDAQ:ALGS
-0.728x
Pioneer Motor Public Company Limited
BK:PIMO
0.043x
Petratherm Ltd
AU:PTR
-0.044x
TOP Engineering Co. Ltd
KQ:065130
0.098x
IT Link
PA:ALITL
0.065x
Jian Sin Industrial Co Ltd
TWO:4502
0.016x
HPP Holdings Bhd
KLSE:0228
0.034x

Annual Cash Flow Conversion Efficiency for Harvard Bioscience Inc (1999–2025)

The table below shows the annual cash flow conversion efficiency of Harvard Bioscience Inc from 1999 to 2025. View HBIO live share price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $13.73 Million $6.73 Million 0.490x +2055.11%
2024-12-31 $63.34 Million $1.44 Million 0.023x -88.16%
2023-12-31 $73.07 Million $14.03 Million 0.192x +1103.48%
2022-12-31 $72.22 Million $1.15 Million 0.016x +5.42%
2021-12-31 $83.40 Million $1.26 Million 0.015x -87.56%
2020-12-31 $76.68 Million $9.33 Million 0.122x +23.54%
2019-12-31 $81.69 Million $8.05 Million 0.099x +245.36%
2018-12-31 $82.18 Million $2.34 Million 0.029x +118.30%
2017-12-31 $80.90 Million $1.06 Million 0.013x -82.48%
2016-12-31 $72.20 Million $5.38 Million 0.075x +720.68%
2015-12-31 $77.60 Million $705.00K 0.009x -80.07%
2014-12-31 $95.47 Million $4.35 Million 0.046x +6.06%
2013-12-31 $94.48 Million $4.06 Million 0.043x -44.46%
2012-12-31 $104.21 Million $8.06 Million 0.077x +16.38%
2011-12-31 $95.50 Million $6.35 Million 0.066x -51.20%
2010-12-31 $90.25 Million $12.29 Million 0.136x -37.91%
2009-12-31 $75.26 Million $16.51 Million 0.219x +59.05%
2008-12-31 $66.72 Million $9.20 Million 0.138x -15.18%
2007-12-31 $74.14 Million $12.05 Million 0.163x +39.88%
2006-12-31 $71.88 Million $8.36 Million 0.116x +53.09%
2005-12-31 $68.42 Million $5.20 Million 0.076x -30.72%
2004-12-31 $104.36 Million $11.44 Million 0.110x +434.44%
2003-12-31 $98.88 Million $2.03 Million 0.021x +126.72%
2002-12-31 $88.38 Million $799.46K 0.009x -85.24%
2001-12-31 $66.81 Million $4.10 Million 0.061x +49.49%
2000-12-31 $52.33 Million $2.15 Million 0.041x -88.81%
1999-12-31 $7.98 Million $2.93 Million 0.367x --

About Harvard Bioscience Inc

NASDAQ:HBIO USA Medical Instruments & Supplies
Market Cap
$36.22 Million
Market Cap Rank
#24121 Global
#5196 in USA
Share Price
$8.03
Change (1 day)
+0.75%
52-Week Range
$0.38 - $8.20
All Time High
$8.47
About

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more